Compare Shell PLC (SHEL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs TransMedics Group Inc — how do they compare? Shell PLC trades at $100.36 (market cap $284.34B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Shell PLC is far larger — about 103.8× TransMedics Group Inc's market cap, and Shell PLC pays a 3.12% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Shell PLC for 90 Days and TransMedics Group Inc for 24 Days on average.
| SHEL | TMDX | |
|---|---|---|
Market Cap | $284.34B | $2.74B |
Volume | 9,097,469 | 949,331 |
Sector | Energy | Health |
52-Week High | $100.20 | $150.42 |
52-Week Low | $70.31 | $61.99 |
Typical Hold Time | 90 Days | 24 Days |
Enterprise Value | $326.04B | $3.13B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $100.18, up 3.44% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with a P/E of 11.08, ROE of 14.35%, and recent earnings beats. Recent developments include the LNG Canada Phase 2 expansion approval, doubling export capacity, positioning Shell for long-term LNG growth. Cash flow remains healthy despite a temporary net outflow in 2025.
Shell presents a compelling investment case with attractive valuation, strong profitability, and strategic LNG expansion. Risks include revenue volatility from oil prices and execution challenges in major projects. Analyst consensus is bullish with a $102.53 price target, suggesting modest upside from current levels.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
